Although there are many markers to assess hypoxia in tumours, such as HIF-1α, X-Box Binding Protein 1 (XBP1), GLUT1 and Vascular endothelial growth factor (VEGF) [7, 8], the results however have been conflicting in various studies. This evidence concerns the gene SLC2A1 and neoplasm.